There was a statistically significant decrease in the tumor-free survival among the CD4-depleted SQV + DMBA treated (12/18) compared to the CD4-depleted SQV treated mice (0/16) (p-value < 0.0001), which was also observed in the non-depleted mice, with SQV only (0/20) compared to SQV + DMBA (16/20) (p-value < 0.0001). The gene discussed is CD4; the disease is neoplasm.